SCHEMBL21362261

SCHEMBL21362261

CN(C)S(=O)(=O)Cc1ccc(C(=O)c2ccc(F)cc2)c(Br)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ6 P48051 1/20 0.37
KCNJ5 P48544 1/20 0.37
KCNJ3 P48549 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
S1PR1 P21453 1/20 0.36
KMT2A Q03164 3/20 0.35
PDK1 Q15118 2/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
EGFR P00533 2/20 0.34
ERBB2 P04626 2/20 0.34
TAS2R14 Q9NYV8 2/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157557 0.86 PTPN1 (0.39) CA12CA1CA2CA9S1PR1
SCHEMBL20157579 0.85 TP53 (0.38) CA12CA1CA2CA9S1PR1
SCHEMBL20157552 0.84 LMNA (0.38) CA12CA1CA2CA9S1PR1
SCHEMBL21351905 0.83 CA2 (0.41) CA12CA1CA2CA9S1PR1
SCHEMBL21362252 0.81 S1PR1 (0.36) CA12CA1CA2CA9S1PR1
SCHEMBL20157516 0.80 ALDH1A1 (0.48) KMT2ATP53LMNAMAPTHTT
SCHEMBL20158130 0.79 EPHX2 (0.37) KMT2AHDAC8HDAC6MAPT
SCHEMBL20157560 0.78 PTPN1 (0.43) S1PR1KMT2AHDAC8HDAC6LMNA
SCHEMBL20157757 0.76 LMNA (0.50) S1PR1KMT2ALMNAMAPTTHRB
SCHEMBL21351924 0.76 TAS2R14 (0.39) CA12CA1CA2CA9TAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 KCNJ6 2570/4885KCNJ5 3004/4885KCNJ3 2151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.